Eric Eisenmann, PharmD, PhD

Assistant Professor

Pharmaceutics and Pharmacology

Research Areas: The Division of Pharmaceutics & Pharmacology, Cancer, Central Nervous System Disorders, Clinical & Pre-Clinical Pharmacology

eisenmann.11@osu.edu

Professional Website

Professional Interests

My current research focuses on determining how targeted and cytotoxic chemotherapy impact the brain and how drug transporters contribute to these effects. Consistent with this research, I am interested in the translational pharmacology of anticancer therapeutics, especially the characterization of preclinical and clinical pharmacokinetics and pharmacodynamics.

Education

2021, PhD in Pharmaceutical Sciences, The Ohio State University
2017, PharmD, Ohio Northern University
2015, BS Psychology, Ohio Northern University

Publications

Supplementary Data from Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen, . 2025 Apr | preprint. doi: 10.1158/2767-9764.28727798.
Supplementary Figure 1 from Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen, . 2025 Apr | preprint. doi: 10.1158/2767-9764.28727795.
Supplementary Figure 2 from Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen, . 2025 Apr | preprint. doi: 10.1158/2767-9764.28727792.
Supplementary Table 1 from Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen, . 2025 Apr | preprint. doi: 10.1158/2767-9764.28727789.
Supplementary Table 2 from Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen, . 2025 Apr | preprint. doi: 10.1158/2767-9764.28727786.
Supplementary Table 3 from Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen, . 2025 Apr | preprint. doi: 10.1158/2767-9764.28727783.
Supplementary Table 4 from Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen, . 2025 Apr | preprint. doi: 10.1158/2767-9764.28727780.
Supplementary Table 5 from Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen, . 2025 Apr | preprint. doi: 10.1158/2767-9764.28727777.
Resazurin dye is an in vivo sensor of kidney tubular function., Kidney international. 2024 Dec | journal-article. doi: 10.1016/j.kint.2024.12.008.
Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Induced Neuropathy and Mitochondrial Toxicity: Limitations of the Poly-γ Hypothesis and the Potential Roles of Autophagy and Drug Transport, Pharmaceutics. 2024 Dec | journal-article. doi: 10.3390/pharmaceutics16121592.
Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen, Cancer Research Communications. 2024 Sep | journal-article. doi: 10.1158/2767-9764.CRC-24-0332.
Pharmacokinetic assessment of low dose decitabine in combination therapies: Development and validation of a sensitive UHPLC-MS/MS method for murine plasma analysis., Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2024 Jun | journal-article. doi: 10.1016/j.jchromb.2024.124209.
Unique Cabozantinib Dosing Considerations in People Living with HIV and Cancer, Clinical Cancer Research. 2023 Dec | journal-article. doi: 10.1158/1078-0432.CCR-23-2351.
Exploring pharmacokinetics of talazoparib in ABCB1/ABCG2-deficient mice using a novel UHPLC-MS/MS method, Heliyon. 2023 Nov | journal-article. doi: 10.1016/j.heliyon.2023.e20972.
TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion, Cancers. 2022 Dec | journal-article. doi: 10.3390/cancers15010029.
Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B, Molecules. 2022 Oct | journal-article. doi: 10.3390/molecules27206815.
A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities, Pharmaceutics. 2022 Sep | journal-article. doi: 10.3390/pharmaceutics14091933.
BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors, Blood Advances. 2022 Sep | journal-article. doi: 10.1182/bloodadvances.2022007952.
MATE1 Deficiency Exacerbates Dofetilide-Induced Proarrhythmia, International Journal of Molecular Sciences. 2022 Aug | journal-article. doi: 10.3390/ijms23158607.
Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination, Pharmaceutics. 2022 Mar | journal-article. doi: 10.3390/pharmaceutics14040694.
Boosting the oral bioavailability of anticancer drugs through intentional drug–drug interactions, Basic & Clinical Pharmacology & Toxicology. 2022 Jan | journal-article. doi: 10.1111/bcpt.13623.
Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition, Cancer Research Communications. 2021 Nov | journal-article. doi: 10.1158/2767-9764.CRC-21-0076.
Targeting OCT3 attenuates doxorubicin-induced cardiac injury, Proceedings of the National Academy of Sciences. 2021 Feb | journal-article. doi: 10.1073/pnas.2020168118.
TP-0903 is active in models of drug-resistant acute myeloid leukemia, JCI Insight. 2020 Dec | journal-article. doi: 10.1172/jci.insight.140169.
Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors, Pharmaceutics. 2020 Sep | journal-article. doi: 10.3390/pharmaceutics12090856.
Development and validation of a sensitive UHPLC-MS/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies, Journal of Chromatography B. 2020 Sep | journal-article. doi: 10.1016/j.jchromb.2020.122176.
Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib, Pharmaceutics. 2020 Aug | journal-article. doi: 10.3390/pharmaceutics12090788.
Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice, Journal of Clinical Investigation. 2020 Jun | journal-article. doi: 10.1172/jci136796.
Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies, Clinical Cancer Research. 2019 Dec | journal-article. doi: 10.1158/1078-0432.CCR-19-0470.
Myocardial hypersensitivity to ischemic injury is not reversed by clonidine or propranolol in a predator-based rat model of posttraumatic stress disorder, Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2019 Mar | journal-article. doi: 10.1016/j.pnpbp.2018.09.003.
Predator-based psychosocial stress model of PTSD differentially influences voluntary ethanol consumption depending on methodology, Alcohol. 2018 Aug | journal-article. doi: 10.1016/j.alcohol.2018.01.004.
Acute Stress Decreases but Chronic Stress Increases Myocardial Sensitivity to Ischemic Injury in Rodents, Frontiers in Psychiatry. 2016 Apr | journal-article. doi: 10.3389/fpsyt.2016.00071.
Sex-dependent effects of sleep deprivation on myocardial sensitivity to ischemic injury, Stress. 2016 Mar | journal-article. doi: 10.3109/10253890.2016.1152469.
Sex-dependent effects of chronic psychosocial stress on myocardial sensitivity to ischemic injury, Stress. 2015 Oct | journal-article. doi: 10.3109/10253890.2015.1087505.